Health
your username
5 hours ago
The Northern District of California on Thursday denied summary judgment to both parties in a consolidated antitrust class action over diabetes drug Glumetza.
The plaintiffs at the helm of the class, including pharmaceutical retailers such as Meijer and Walgreens, filed suit in September 2019 against a handful of drug manufacturers for allegedly colluding to inflate the price of Glumetza to be over 50 times more expensive than the competitive price, “steal(ing) more than $2.8 billion from Glumetza purchasers,” according to the complaint. The defendants allegedly accomplished this through a “pay for delay” scheme: Glumetza manufacturer Depomed Inc. paid Lupin Pharmaceuticals Inc. — which had plans to enter the market with a generic competing product — to delay bringing its product to market after the companies settled a patent litigation, according to the plaintiffs.